乐伐替尼的药理和临床评价

Abstract

乐伐替尼是一种口服多靶点酪氨酸激酶抑制剂,2015年2月13日获得美国食品药品监督管理局(FDA)批准,用于治疗局部复发或转移病灶进展性放射性碘(131I)难治性分化型甲状腺癌(RR-DTC)。本文对乐伐替尼的药理作用、药动学、临床评价、安全性以及药物相互作用等进行了综述。

Lenvatinib is an oral,multitargeted tyrosine kinase inhibitor. It was approved for the treatment of locally recurrent or metastatic,progressive,radioactive iodine-refractory differentiated thyroid cancer by FDA in February 13,2015. The pharmacology,pharmacokinetics,clinical evaluation,safety,and drug interactions of lenvatinib were reviewed in this paper.